NKF advises NewBiologix on its USD 50m series A financing

NewBiologix, a technology company developing a proprietary platform focused on engineering cell lines used to manufacture gene and cell therapies, raised USD 50 million in series A financing. The round was led by Recipharm (an EQT IX portfolio company) with participation from the company co-founders and serial entrepreneurs, Igor Fish and Nicolas Mermod. The company intends to use the funds to begin beta testing of the cell line prototypes with key collaborators by 2024.

NewBiologix is developing a proprietary and breakthrough DNA integration platform for the advanced engineering of human and mammalian cell lines. It is currently focused on recombinant adeno-associated virus (rAAV) vectors, the preferred delivery vehicle for gene therapies. The Lausanne based company  anticipates making viral production cell lines commercially available by 2026.

Niederer Kraft Frey advised NewBiologix on its launch and its USD 50 million series A financing. The team was led by corporate/m&a and technology partner Jacques Bonvin (pictured left), working with partner Andrea Wuerzner (corporate/m&a, pictured right) and junior associate Boris Catzeflis (technology).